Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (referred to as "Therapix" or the "Company") covers the month of May 2020. The report details a significant corporate restructuring involving a joint venture transaction closed on May 18, 2020, and addresses the Company's compliance status with Nasdaq Capital Market listing requirements regarding stockholders' equity.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) for the period. Instead, it focuses on specific transaction values and equity metrics:
- Joint Venture Transaction: Therapix's subsidiary, Evero Health Ltd. ("Evero"), acquired approximately 35% of Coeruleus Ltd. (a developer of flumazenil-based medications) from Capital Point Ltd.
- Asset Transfer: Therapix transferred its THX-110 sleep technology to Evero, which will now be fully owned by Evero.
- Equity Issuance: Evero issued 176,470 ordinary shares (representing 15% of its capital) to Capital Point as consideration.
- Warrant Issuance: Therapix issued a warrant to Capital Point to purchase $340,000 of Therapix American Depositary Shares (ADSs). The exercise price is variable based on the closing price on the exercise date, payable via transfer of Evero shares valued at $35.50 each.
- Stockholders' Equity: Following the transaction and a prior $1.25 million public offering (closed April 3, 2020), the Company believes its stockholders' equity exceeds the Nasdaq requirement of $2.5 million.
Material Changes
The primary material change is the formation of a joint venture with Capital Point Ltd. and Evero Health Ltd., resulting in:
- Evero gaining a 35% stake in Coeruleus Ltd.
- Therapix divesting its THX-110 sleep technology to Evero.
- The issuance of a warrant to Capital Point for future Therapix ADS purchases.
- A potential improvement in Therapix's stockholders' equity position to meet Nasdaq listing standards.
Outlook, Risks, and Contingencies
Listing Compliance Risk: While management believes the Company now meets the $2.5 million stockholders' equity threshold required by Nasdaq Listing Rule 5550(b), there is no assurance that compliance can be demonstrated to Nasdaq's satisfaction. Failure to demonstrate compliance could result in prompt delisting from the Nasdaq Capital Market.
Forward-Looking Statements: The report contains forward-looking statements regarding the joint venture and regulatory compliance. Actual results may differ materially due to risks and uncertainties, including those detailed in the Company's Annual Report on Form 20-F filed on May 15, 2019.
Investor Verification Checklist
- Verify the final determination by Nasdaq regarding Therapix's compliance with the $2.5 million stockholders' equity rule.
- Review the full text of the Share Transfer Agreement (Exhibit 99.1), Asset Purchase Agreement (Exhibit 99.2), and Warrant (Exhibit 99.3) for specific terms and conditions.
- Monitor the status of the THX-110 technology transfer and its impact on Therapix's future product pipeline.
- Assess the financial health and development progress of Coeruleus Ltd., given Evero's new 35% ownership stake.